PAC Urología-1 A1
Contenido
REFERENCIAS
    TUMORES TESTICULARES.
    ASPECTOS HISTOPATOLÓGICOS

  1. Brown LM, Pottern LM, Hoover RN. Testicular cancer in the United States: trends in incidence and mortality.Int J Epidemol 1986;15:164-170.

  2. Davis JM.Testicular cancer in England and Wales: some epidemiologic aspects. Lancet 1981; 1:928-932.

  3. Kratzik C, Hinginger P, Kuzmitis R, et al. HLA -antigen distribution in seminoma. Hcg-positive seminoma and non-seminomatous tumours of the testis. Urol Res 1989; 17:377-380.

  4. Jacobsen GK, Henriksen OB, Der Maase HV. Carcinoma in situ of testicular tissue adjacent to malignant germ-cell tumors. A study of 105 cases.Cancer 1981; 47:2660-2662.

  5. Klein FA, Melamed MR, Whitmore WF Jr.Intratubular malignant germ cells (carcinoma in situ) accompanying invasive testicular germ cell tumors. J Urol 1985;133: 413-415.

  6. Babaian RJ, Zagars GK.Testicular seminoma: The MD. Anderson experience, an analysis of pathological and patients characteristic and treatment recomendations. J Urol 1988;139:311-315.

  7. Mostofi FK, Price EB Jr. Atlas of tumor pathology, Second Series, fascicle 8. Tumors of the male genital system. Washington, DC: Armed Forces Institute of Pathology, 1973.

  8. Scully RE.Spermatocytic seminoma of the testis: A report of 3 cases and review of the literature. Cancer 1961;14:788-794.

  9. Albores-Saavedra J, Huffman H, Alvarado-Cabrero Y, Ayala Alberto. Anaplastic spermatocytic seminoma.Hum Pathol 1996;27:650-655.

  10. Pierce GB, Abell MR.Embryonal carcinoma of the testis.Pathol Annu 1970; 5:27-60.

  11. Vugrin D, Chen A, Feigl P, Laszlo J. Embryonal carcinoma of the testis. Cancer 1988;61:2348-352.

  12. Ulbright TM.Germ cell neoplasms of the testis. Am J Surg Pathol 1993;17:1075 -1091.

  13. Ulbright TM, Roth LM, Brodhecker CA. Yolk sac differentiation in germ cell tumors: a morphologic study of 50 cases with emphasis on hepatic, enteric and parietal yolk sac features. Am J Surg Pathol 1986; 10:151-164.

  14. Parkinson C, Beilby JOW. Features of prognostic significance in testicular germ cell tumors. J Clin Pathol 1977; 30:113-119.

  15. Ulbright TM. Young RH, Scully RE. Trophoblastic tumors of the testis other than classic chorio- carcinoma. Am J Surg Pathol 1997; 21:282-288.

  16. Lawrence WD, Young RH, Scully RE. Sex cord stromal tumors: Contemporary issues in sugical pathology, Vol 7., Chap 4. New York: Churchill Livingston,1986.

  17. Kim Y, Young RH, Scully RE. Leydig cell tumors of the testis: A clinico-pathological analysis of 40 cases and review of the literature. Am J Surg Pathol 1985; 9:177 -192.

  18. Cantu JM, Rivera H, Ocampo-Campos R, et al. Peutz-Jeghers syndrome with feminizing Sertoli cell tumor. Cancer 1980; 46:223-228.

  19. Young RH, Scully RE. Testicular tumors. American Society of Clinical Pathologists. 1990.

  20. Paladagur RR, Bearman RM, Rappaport H. Malignant lymphoma with primary manifestations in the gonad: A clinico-pathologic study of 38 patients. Cancer 1980;45:561-571.

  21. Morgan AD.Inflamatory lesions simulating malignancy.Br J Urol 1964; 36:95-102.

  22. Levin HS, Mostofi FK. Symptomatic plasmocytoma of the testis. Cancer 1970;25: 1193-1203.

  23. Haupt HM, Mann RB, Trump DL, Abeloff MD. Metastatic carcinoma involving the testis: Clinical and pathologic distinction from primary testicular neoplasms. Cancer 1984; 54: 709-714.

    TUMORES TESTICULARES.
    ASPECTOS CLÍNICOS

  1. Registro Nacional de Cáncer. D.G.G. México: Secretaría de Salud, 1989.

  2. Mostofi FK. Proceedings: testicular tumors. Epidemiologic, etiologic and pathologic features. Cancer 1973;32:1186.

  3. Silverberg E. Cancer statistics, 1985. CA 1985;35:19.

  4. Clemmesen J. A doubling of morbidity from testis carcinoma in Copenhagen, 1943-1962. Acta Path Microbiol Scand 1968;72:348.

  5. Petersen GR, Lee JA. Secular trends of malignant tumors of the testis in white men. JNCI 1972;49:339.

  6. Schottenfeld D, Warshauer ME, Sherlock S. The epidemiology of testicular cancer in young adults. Am J Epidemiol 1980;112:232.

  7. Coldman AJ, Elwood JM, Gallagher RP. Sport activities and risk of testicular cancer. Br J Cancer 1982;46: 749.

  8. Depue RH, Pike MC, Henderson BE. Estrogen exposure during gestation and risk of testicular cancer. JNCL 1983;71: 1151.

  9. Henderson BE, Benton B, Jing J, et al. Risk factors for cancer of the testis in young men. Int J Cancer 1979;23: 598.

  10. Dow JA, Mostofi FK. Testicular tumors following orchiopexy. S Med J 1967;60:193.

  11. Pottern LM, Browin LM, Hoover RN, et al. Testicular cancer risk among young men: role of cryptorchidism and inguinal hernia. JNCL 1985;74:377.

  12. Depue RH. Maternal and gestational factors affecting the risk of cryptorchidism and inguinal hernia. Int J Epidemiol 1984;13:311.

  13. Skakkebaek NE, Berthelsen JG. Carcinoma in situ of the testis and invasive growth of different types of germ cell tumours. A revised germ cell theory. Int J Androl, Suppl 1981;4:26.

  14. Skakkebaek NE, Berthelsen JG. Carcinoma in situ of testis and orchidectomy. Lancet, 1978;2:204.

  15. Berthelsen JG, Skakkebaek NE, von der Maase H, et al. Screening for carcinoma in situ of the contralateral testis in patients with germinal teticular cancer. Br Med J 1987; 285: 1683.

  16. Von der Maase H, Giwercman A, Mller J, et al. Management of carcinoma in situ. Intl J Androl 1987;10:209.

  17. Scully RE. Neoplasia associated with anomalous sexual development and abdormal sex chromosomes. Pediatr & Adol Endocr 1981;8:203.

  18. Miller J, Skakkebaek NE. Testicular carcinoma in situ in children with the androgen insensitivity (testicular feminization) syndrome. Br Med J 1984;288: 1419.

  19. Miller J, Skakkebaek NE, Ritzen M, Ploen L. Carcinoma in situ of the testis in children with 45,X/46,XY gonadal dysgenesis. J Pediatr 1985;106:431.

  20. Pryor LP, Cameron KM, Chilton CP, et al. Carcinoma in situ in testicular biopsies from men presenting with infertility. Br J Urol1983; 55:780.

  21. Sinke RJ, Suijkerbuijk RF, de Jong B, Oosterhuis JW, Geurts van Kessel A. Uniparental origin of i(12p) in human germ cell tumors. Genes Chrom Cancer 1993;6:161.

  22. Atkin NB, Baker MC. i(12p): A specific chromosomal marker in seminoma and malignant teratoma of the testis? Cancer Genet Cytogenet 1983;10:199.

  23. van Echten J, Oosterhuis J, Looijega LHJ, van de Pol M, Wersema J, te Meerman GJ, Schraffordt Koops H, Sleijfer Dth, de Jong B. No recurrent structural abnormalities apart from i(12p) in primary germ cell tumors of the adult testis. Genes Chrom Cancer 1995;14:133.

  24. Geurts van Kessel A, Suijkerbhujk RF, Sinke RJ, Looijega L, Oosterhuis JW, de Jong B. Molecular cytogenetics of human germ cell tumors: i(12p) and related chromosomal anormalies. Eur Urol 1993;23:23.

  25. Saikevych IA, Mayer M, Brooks VP, Michael S. Cytogenetic study of a testicular tumor in a translocation (13;14) carrier. Cancer Genet Cytogenet 1987;26:199.

  26. Reilly PA, Heerema NA, Sledge GW, Palmer CG. Unusual distribution of chromosome 12 in a testicular germ-cell tumor cell line (833K) and its cisplatin-resistant derivative (64CP9). Cancer Genet Cytogenet 1993;68: 114.

  27. Suijkerbuijk RF, Sinke RJ, Meloni AM. Parrington MJ, van Echten J, de Jong B, Oosterhuis JW, Sandber AA, Geurts van Kessel A. Overrepresentation of chromosome 12p sequences and karyotypic evolution in i(12p)-negative testicular germ cell tumors revealed by fluorescence in situ hybridization. Cancer Genet Cytogenet 1993;70:85.

  28. de Jong B, Oosterhuis JW, Castedo SM, Vos A, te Meerman GJ. Pathogenesis of adult testicular germ cell tumors. A cytogenetic model. Cancer Genet Cytogenet 1990;48: 143.

  29. Castedo SM, de Jong B, Oosterhuis JW, Idenburg VJ, Seruca R, Buist J, te Meerman GH, Dam A, Schraffordt Koops H, Sleijfer DT. Chromosomal changes in mature residual teratomas following poychemotherapy. Cancer Res 1989;49:672.

  30. Samaniego F, Rodríguez F, Houldworth J, Murty VV, Ladanyi M, Lele KP, Chen QG, Dmitrovsky E, Geller NL, Reuter V, Jhanwar SC, Bosl GJ, Chaganti RS. Cytogenetic and molecular analysis of human male germ cell tumors: chromosome 12 abnormalities and gene amplification. Genes Chrom Cancer 1990;1:289.

  31. Bosl GH, Ilson DH, Rodríguez E, Motzer RJ, Reuter VE, Chaganti RS. Clinical relevance of the y (12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994;86: 349.

  32. Burke AP, Mostofi FK. Intratubular malignant germ cells in testicular biopsies: Clinical course and identification by staining for placental alkaline phosphatase. Mod Pathol 1988;1:475.

  33. Friedman NB, Moore RA. Tumors of the testis: A report of 922 cases. Mil Surg 1946; 99: 573.

  34. Javadpur N, Young YD. Prognostic factors in nonseminomatous testicular cancer. J Urol 1986; 135:497.

  35. Wilson JM, Woodhead DM. Prognostic and therapeutic implications of urinary gonadotropin levels in the management of testicular neoplasia. J Urol 1972; 108:754.

  36. Altadonna V, Snyder HM, Rosenberg HK, et al. Simple cyst of the testis in children. Preoperative diagnosis by ultrasound and excision with testicular preservation. J Urol 1988; 140:1505.

  37. Vaitukaitis JL, Ross GT. Recent advances in the evaluating of gonadotropic hormones. En: Cruger WP, Copgging CH, Hancock EW, ed. Annual Review of Medicine. Palo Alto, Annual Reviews, Inc., 1973, volume 24, 295-302.

  38. Javadpour N. The role of biologic tumor markers in testicular cancer. Cancer 1980; 45: 1755.

  39. Bracken RB, Johnson DE, Samuels ML. Alphafetoprotein determinations in germ cell tumors of the testis. Urology 1975;6:382.

  40. Talerman A, Haije WG. Alpha-fetoprotein and germ cell tumors: A possible role of yolk sac tumor in production of alphafetoprotein. Cancer 1974;34:1722.

  41. Robertson AG, Read G. The value of lactate dehydrogenase as a nonspecific tumour marker for seminoma of the testis. Br J Cancer 1982; 46:994.

  42. Scardino PT, Waldmann TA, McIntire KR, Javadpour N. The value of serum tumor markers in staging and prognosis of germ cell tumors of the testis. J Urol 1977; 118:994.

  43. Toner GC, Geller NL, Tan C. Serum tumor marker half life during chemotherapy allows early prediction of complete response and survival in non seminomatous germ cell tumors. Cancer Res 1990; 50:5904.


  44. Skinner DG, Scardino PT. Relevance of biochemical tumor markers and lymphadenectomy in management of nonseminomatous testis tumors: current perspectives. J Urol 1980; 123:378.


  45. de Graaaff WE, Oosterhuis JW, de Jong B, Dam A, van Putten WL, Castedo SM, Sleikfer DT, Schraffordt Koops H. Ploidy of testicular carcinoma in situ. Lab Invest 1992; 66:166.


  46. Sandberg AA, Meloni AM, Suijkerbuijk RF. Reviews of chromosome studies in urological tumores. III. Citogenetics and genes in testicular tumores. J Urol 1996; 155:1531.


  47. Standbridge EJ, Flandermeyer RR, Daniels DW, Nelson-Rees WA. Specific chromosome loss associates with the expression of tumorigenicity in human cell hybrids. Somatic Cell Genet 1981; 7:699.

  48. Bosl CS, Ilson DH, Rodríguez RD, Motzer RJ, Reuter VE, Chaganti RS. Clinical relevance ot the i(12p) marker chromosome in germ cell tumors. J Natl Cancer Inst 1994; 86:349.

  49. Berger CS, Pennington RD, Dobbs R, Haddad, Sandberg AA. Cytogenetic aspects of germ cell tumors of the testis. Cancer Genet Cytogenet 1987 38:147.

  50. Oosterhuis JW, Looikenga LH. The biology of human germ cell tumores: retrospective speculations and new perspectives. Eur Urol 1993; 23: 245.

  51. Damjanov Y. Is seminoma a relative or a precursor of embryonal carcinoma ? Lab Invest 1989; 60:1 .

  52. Friedman NB, Moore RA. Tumors of the testis. A report on 922 cases. Milit Surgeon 1946; 99:573.

  53. Dixon FJ, Moore RA. Tumors of the male sex organs. Fascicle 31b and 32, Atlas of tumor pathology. Whashington. Armed Forces Institute of Pathology, 1952.

  54. Mostofi FK, Price EB. Tumors of the male genital system. Fascicle 8, Atlas of tumor pathology. Washington. Armed Forces Institute of Pathology, 1973.

  55. Skakkebaek NE. Possible carcinoma in situ of the testis. Lancet 1972; 2:516.

  56. Pugh RCB. Pathology of the testis. Oxford: Blackwell Scientific Publications, 1976.

  57. Giwercmann A, Muller J, Skakkegaek NE. Carcinoma in situ of the undescended testis. Semin Urol 1988; 6: 110.

  58. Krabbe S, Skakkebaek NE, Berthelsen JG. High incidence of undetected neoplasia in maldescended testes. Lancet 1979; 1: 999.

  59. Von der Maase H, Rorth M, Walbom-Jorgensen S. Carcinoma in situ of contralateral testis in patients with testicular germ cell cancer. Study of 27 cases in 500 patients. Br Med J 1986; 293: 1389.

  60. Cassio A, Cacciari E D, Errico A. Incidence of intratubular germ cell neoplasia in androgen insensitivity syndrome. Acta Endocrinol (Copenh) 1990; 123:416.

  61. Oliver RTD, Stephenson CA, Parkinson CA. Germ cell tumours of the testicle as a model of MHC influence on human malignancy. Lancet 1986; 1:1506.

  62. Mostofi F. Proceedings. testicular tumors. Epidemiologic, etiologic and pathologic featurs. Cancer1973; 32:1186.

  63. Jirsek JE. Development of the genital system and male pseudohermaphroditism. Baltimore: Johns Hopkins University Press, 1971.

  64. Ray B, Hajdu ST, Whitmore WF. Distribution of retroperitoneal lymph node metastases in testicular germinal tumors. Cancer 1974; 33:340.

  65. Javadpour N, Bergman SM. Recent advances in testicular tumors. Curr Prob Surg February 1978.

  66. Boileau MA. Germ cell tumors of the testis. Overview. En: Jhonson DE, Boileau, ed. Genitourinary tumores. New York: Grune & Straton, 1983.

  67. Fraley EE, Lange PH, Williams RD. Staging of early nonseminomatous germ cell testicular cancer. Cancer 1980; 45:1762.

  68. Schaner EG, Chang AE, Doppman JL. Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. AJR 1978; 131:51.

  69. Jochelson MS, Garnic MB, Balikian JP. The efficay of routine whole lung tomography in germ cell tumors. Cancer 1984; 54:1007.

  70. Vugrin D, Whitmore WF, Nisselbaum J. Correlation of serum tumor markers and lymphangiography with degrees of nodal involvement in surgical stage II testis cancer. J Urol 1982;127:683.

  71. Wobbes T, Blom JM, Oldhoff J. Lymphography in the diagnosis of non seminoma tumors of the testis. J Surg Oncol 1982; 19:1.

  72. Kademinan M, Wietanen G. Accuracy of bipedal lymphangiography in testicular tumors. Urology 1977; 9:218.

  73. Richie JP, Garnick MB, Finberg H. Computarized tomography. How accurate for abdominal staging of testis tumors? J Urol 1982; 127:715.

  74. Lee JC, McClennan BL, Stanley RJ. Computed tomograpy in the staging of testicular neoplasms. Radiology 1979; 130:387.

  75. Thomas G. Controversies in the management of testicular seminoma. Cancer 1985; 55:2296.

  76. Hamilton CR, Horwich A, Easton D. Radiotherapy for stage I seminoma testis. Results of treatment and complications. Radiother Oncol 1986; 6: 115.

  77. Zagars GK, Babaian RJ. Stage I testicular seminoma. Rationale for post orchiectomy radiation therapy. Int J Radiat Oncol Biol Phys 1987; 13:155.

  78. Duncan W, Munro AJ. The management of testicular seminoma. Edimburg 1970- 1981. Br J Cancer 1987; 55: 443.

  79. Fossa SD, Aass N, Kaalhus L. Radiotherapy for testicular seminoma stage I: Treatment results and long-term postirradiation morbidity in 365 patients. Int J Radiat Oncol Biol Phys 1989; 16:383.

  80. Kellokumpu-Lehtinen P, Halme A. Results of treatment in irradiated testicular seminoma patients. Radiother Oncol 1990; 18:1.

  81. Sommer K, Brockmann WP, Hubener KH. Treatment results and acute and late toxicity of radiation therapy for testicular seminoma. Cancer 1990; 66:259.

  82. Cortes HD, Ayala HJR, Suarez CJ. Seminoma testicular. Oncologia 1987; 4: 9.

  83. Ayala HJR, Suarez CJ, Gaona JG. Tratamiento del seminoma testicular con megavoltaje. Análisis de 100 casos. Bol Col Mex Urol 1987; 1:12.

  84. Coia LR, Hanks GE. Complications from large field intermediate doses infadiaphragmatic radiation. An analysis of the patterns of care outcome studies for Hodgkin's disease and seminoma. Int J Radiat Oncol Biol Phys 1988; 15:29.

  85. Hamilton C, Horwich, A, Easton D. Radiotherapy for stage I seminoma testis. Results of treatment and complications. Radiol Oncol 1986; 6:115.

  86. Fraas BA, Kinsella T, Harrington FS. Peripheral dose to the testes. The design and clinical use of a practical and effective gonadal shield. Int J Radiat Oncol Biol Phys 1985; 11:609.

  87. Hay JH, Duncan W, Kerr GR. Subsequent malignancies in patients irradiated for testicular tumours. Br J Radiol 1984; 57:597.

  88. Coleman MP, Bell CMJ, Fraser P. Second primary malignancy after Hodgkin's disease, ovarian cacner and cancer of the testis. A popoulation based cohort study. Br J Cancer 1987; 56:349.

  89. Duschene GM, horwich A, Dearnaley DP. Orchidectomy alone for stage I seminoma of the testis. Cancer 1990; 65:1115.

  90. Thomas GM. Surveillance in stage I seminoma of the testis. Urol Clin North Am 1993; 1:85.

  91. Thomas GM, Sturgeon JF, Alison R. A study of post-orchiectomy surveillance in stage I testicular seminoma. J Urol 1989;142:313.

  92. Evensen JF, Fossa SD, Kjellevold K. Testicular seminoma. Analysis of treatment and failure for stage II disease. Radiother Oncol 1985;4: 55-61.

  93. Gregory C, Peckham MJ. Results of radiotherapy for stage II testicular seminoma. Radiother Oncol 6:285, 1986.

  94. Thomas GM, Rider WD, Dembo AJ. Seminoma of the testis. Results of treatment and patterns of failure after radiation therapy. Int J Radiat Oncol Biol Phys 1982;8:165.

  95. Horwich A, Dearnaley DP. Treatment of seminoma. Semin Oncol 1992;2:171.

  96. Thomas G. Management of metastatic seminoma. Role of radiotherapy. En: Horwich A ed. Testicular cancer- Clinical investigation and management. New York: Chapman and Hall Medical, 1991: 211.

  97. Mason BR, Kearsley JH. Radiotherapy for stage II testicular seminoma. The prognostic influence of tumor bulk. J Clin Oncol 1988;6:1856.

  98. Einhorn LH, Williams SD, Mandelbaum I. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981;48:904.

  99. Van Oosterom AT, Williams SD, Cortes H. The treatment of metastatic seminoma with combination chemotherapy. En: Jones WG, Ward AM, Anderson CK ed. Germ cell tumours II. Oxford, England: Pergamon, 1986:229.

  100. Clemm C, Hartenstein R, Willich N. Combination chemotherapy with vinblastine, ifosfamide and cisplatin in bulky seminoma. Acta Oncol 1989;28:231.

  101. Peckham MJ, Horwich A, Blackmore C. Etoposide and cisplatin with or without bleomycin as first-line chemotherapy in patients with small-volume metastases of testicular nonseminoma. Cancer Treat Rep 1985;69:483.

  102. Stanton GF, Bosl GJ, Whitmore WF. VAB-6 as initial treatment of patients with advanced seminoma. J Clin Oncol 1985;3:336.

  103. Friedman EL, Garnick MB, Stomper PC. Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 1985; 3:1325.

  104. Logothetis CJ, Samuels ML, Ogden SL. Cyclophosphamide and sequential cisplatin for advanced seminoma. Long-term follow-up in 52 patients. J Urol 1987;138:789.

  105. Herr HW, Bosl G. Residual mass after chemotherapy for seminoma. Changing concepts of management. J Urol 1987;137: 1234.

  106. Fossa SD, Borge L, Gass N. The treatment of advanced metastatic seminoma. Experience in 55 cases. J Clin Oncol 1987;5:1071.

  107. Friedman EL, Garnick MB, Stomper PC. Therapeutic guidelines and results in advanced seminoma. J Clin Oncol 1985; 3:1325.

  108. Peckham MJ, Horwich A, Hendry WF. Advanced seminoma treatment with cisplatinum based combination chemotherapy or carboplatin. Br J Cancer 1985;52:7.

  109. Loehrer PJ, Birch R, Williams SD. Chemotherapy of metastatic seminoma. The Southeastern Cancer Study Group experience. J Clin Oncol 1987;5:1212.

  110. Motzer R, Bosl G, Heelan R. Residual mass. An indication for further therapy in patients with advanced seminoma following systemic chemotherapy. J Clin Oncol 1987;5:1064.

  111. Pizzocaro G, Zanoni F, Salvioni R. Difficulties of a sur veillance study omitting retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germ cell tumors of the testis. J Urol 1987;138:1393.

  112. Crawford SM, Rusting GJS, Begent RHJ. Safety of surveillance in the management of stage I anaplastic germ cell tumours of the testis. Br J Urol 1988; 61:250.

  113. Sogani PC. Evolution of the management of stage I nonseminomatous germ-cell tumors of the testis. Urol Clin North Am 1991;18:561.

  114. Hosking P, Dilly S, Easton D. Prognostic factors in stage I non-seminomatous germ-cell testicular tumours managed by orchiec- tomy and surveillance. Implications for adjuvant chemotherapy. J Clin Oncol 1986;4:1031.

  115. Jewett MAS. Surveillance after orchiectomy for patients with clinical stage I non-seminomatous testis tumors. En Post Graduate Course 11. Testicular Malignancy Update. Presentedat the 86th Annual American Urological Association Meeting, June 1991, pp15.

  116. Freedman LS, Parkinson MC, Jones WG. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomuy alone. Lancet 1987;2:294.

  117. Rorth M, Jacobsen GK, von der Masse H. Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. J Clin Oncol 1991;9:1543.

  118. Read G, Stenning SP, Cullen MH. Prospective study of surveillance for stage I testicular non seminomatous germ cell tumors. A study by the Medical Research Council (abstract 523). Proc Am Soc Clin Oncol, 1991:165.

  119. Freiha F, Torti F. Orchiectomy only for clinical stage I non seminomatous germ cell testis tumors. Comparision with pathologic stage I disease. Urology 1989;34:347.

  120. Raghavan D, Colls B, Levi J. Surveillance for stage I non-seminomatous germ cell tumours of the testis. The optimal protocol has not been defined. Br J Urol 1988;61:522.

  121. Thompson PI, Nixon J, Harvey VJ. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol 1988;6:1597.

  122. Gerlderman WA, Scharaffford KH,Sleijfer DT. Orchidectomy alone in stage I nonseminomatous testicular germ cell tumors. Cancer 1987;59: 578.

  123. DewarJ, Spagnolo DV, Jamrozik KD. Predicting relapse in stage I non seminomatous germ cell tumours of the testis. Lancet 1987;1:454.

  124. Swanson DA, Johnson DE. M.D. Anderson experience with surveillance for clinical stage I disease. En: Johnson DE, Logothetis CJ, Von Eschenbach AC, eds. Systemic therapy for genitourinary cancers. Chicago: Year Book Medical Publishers, 1989:304.

  125. Vugrin D, Whitmore WF, Cvitkovic E. Adjuvant chemotherapy in nonseminomatous testis cancer. Mini-VaB regimen. Long term follow-up. J Urol 198l;126:49.

  126. Fung CY, Kalish LA, Brodsky GL. Stage I nonseminomatous germ cell testicular tumor. Prediction of metastatic potencial by primary histopathology. J Clin Oncol 1988;6:1467.

  127. Sesterhenn IA, Weiss RB, Mostofi FK. Prognosis and other clinical correlates of pathologic review in stage I and II testicular carcinoma. A report from the Testicular Cancer Intergroup study. J Clin Oncol 1992;10:69.

  128. McLeod DG, Weiss RB, Stablein DM. Staging relationships and outcome in early stage testicular cancer. A report from the Testicular Cancer Intergroup study. J Urol 1991;145:1178.

  129. Moriyama N, Daly JJ, Keating MA. Vascular invasion as a prognosticator of metastatic disease in nonseminomatous germ cell tumors of the testis. Importance in surveillance only protocols. Cancer 1985;56:2492.

  130. Sternberg CN. Role of primary chemotherapy in stage I and low volume stage II nonseminomatous germ cell testis tumors. Urol Clin North Am 1993;1:93.

  131. Javadpour N, Young JD. Prognostic factors in nonseminomatous testicular cancer. J Urol 1986;135:497.

  132. Rodríguez PN, Hafez GR, Meesing EM. Nonseminomatous germ cell tumor of the testicle. Does extensive staging of the primary tumor predict the likelihood of metastatic disease? J Urol 1986;136:604.

  133. Hoeltl W, Kosak D, Pont J. Testicular cancer. Prognostic implications of vascular invasion. J Urol 1987;137:683.

  134. Klepp O, Olsson AM, Henrikson H. Prognostic factors in clinical stage I non-seminomatous germ cell tumors of the testis. Multivariate analysis on a prospective multicenter study. J Clin Oncol 1990;8:509.

  135. Fung CY, Garnick MB. Clinical stage I carcinoma of the testis. A review. J Clin Oncol 1988;6:734.

  136. Dunphy CH, Ayala AG, Swanson DA. Clinical stage I nonseminomatous and mixed germ cell tumors of the testis. A clinicopathologic study of 93 patients on a surveillance protocol after orchiectomy alone. Cancer 1988;62:1202.

  137. Jacobsen GK, Rorth M, Osterlind K. Histopathological features in stage I non-seminomatous testicular germ cell tumours correlated to relapse. APMIS 1990;98:377.

  138. Rorth M, von der Maasse H, Nielsen ES. Orchidectomy alone versus orchidectomy plus radiotherapy in stage I nonseminomatous testicular cancer. A randomized study by the Danish Testicular Carcinoma Study Group. Int J Androl 1987;10:255.

  139. Gimmi C, Sonntag R, Brunner K. Adjuvant treatment of high risk clinical stage I testicular carcinoma with cisplatin, bleomycin and vinblastin or etoposide (abstract 542). Proc Am Soc Clin Oncol, 1990:140.

  140. Studder UE, Sonntag RW, Caldeoni A. Adjuvant chemotherapy in patients with high- risk stage I non-seminomatous germ cell tumors (abstract 492) J Urol 1992;147: 335A.

  141. Sandeman TF, Yang C. Results of adjuvant chemotherapy for low stage nonseminomatous germ cell tumors of the testis with vascular invasion. Cancer 1988;62:1471.

  142. Mead GM, Stenning SP, Parkinson MC. The second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. J Clin Oncol 1992;10:85.

  143. Madej G, Pawinski A. Risk related adjuvant chemotherapy for stage I non seminoma of the testis. En: New trends indiagnosis and treatment of testicular tumours. Third International Symposium on Advances in Urologic Oncology. San Remo, March 1991:51.

  144. Pont J, Holt W, Kosak D. Risk-adapted treatment choice in stage I non seminomatous testicular germ cell cancer by regarding vascular invasion in the primary tumor. A prospective trial. J Clin Oncol 1990;8:16.

  145. Oliver RTD, Raja MA, Ong J. Pilot study to evaluate impact of a policy of adjuvant chemotherapy for high risk stage I malignant teratoma on overall relapse rate of stage I patients. J Urol 1992;148:1453.

  146. Getaz EP, Beckley S, Fitzpatrick J. Cisplatin induced hemolysis. N Engl J Med 1980; 302:334.

  147. Vogelzang NJ. Prognostic factors in metastatic testicular cancer. Int J Androl 1987;10:225.

  148. Levi JA, Thomson D, Sandeman T. A prospective study of cisplatin based combination chemotherapy in advanced germ cell malignancy. Role of maintenance and long term follow-up. J Clin Oncol 1988;6:1154.

  149. Vermorken JB, Kapteijn TS, Hart AAM. Ototoxicity of cis diaminedcichloroplatinum. Influence of dose, schedule and mode of administration. Eur J Cancer Clin Oncol 1983;19:53.

  150. Boyer M, Raghavan D. Toxicity of treatment of germ cell tumors. Semin Oncol 1992;2:128.


  1. Pizzocaro G, Monfardini S. No adyuvant chemotherapy in selectedpatients with pathologic stage II nonseminomatous germ cell tumors of the testis. J Urol 1984;131:677.

  2. Vogelzang NJ, Fraley EE, Lang PH. Stage II nonseminomatous testicular cancer. A 10 year experience. J Clin Oncol 1983;1:171.

  3. Leiskovsky G, Winberg AC, Skinner DG. Surgical management of early stage nonseminomatous germ cell tumors of thetestis. Semin Urol 1984;2:208.

  4. Ekman EP, Edmyr F. Chemotherapy in non seminomatous testicular tumors stage I. Br J Urol 1981;534:184.

  5. Sandeman TF, Yang C. Results of adjuvant therapy for low stage nonseminomatous germ cell tumors of the testis with vascular invasion. Cancer 1988;62:1471.

  6. Richie JP, Kantoff PW. Is adjuvant chemotherapy necessary for patients with stage B1 testicular cancer? Clin Oncol 1991;9:1393.

  7. Vugrin D, Whitmore W, Cvitkovic E. Adjuvant combination of vinblastine, actinomycin D, bleomycin and chlorambucil following retroperitoneal lymph node dissection for stage II testis tumor. Cancer 1981;47:840.

  8. Williams SD, Stablein DM, Einhorn LH. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317:1433.

  9. Staubitz WJ, Early KS, Magoss IV. Surgical treatment of nonseminomatous germinal testis tumors. Cancer 1973;32.1206.

  10. Donohue JP, Einhorn LH, Perez JM. Improved management of non seminomatous testis tumors. Cancer 1978;42:2903.

  11. Williams SD, Stablein DM, Einhorn LH. Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 1987;317:1433.

  12. Fossa SD, Aass N, Ous S. Hystology of tumorresiduals folowing chemotherapy in patients with advanced non-seminmatous testicular cancer. J Urol 1989;142:1239.

  13. Carter GE, Lieskovsky G, Skinner DG. Reassessment of the role of adjuntive surgical therapy in the treatment of advanced germ cell tumors. J Urol 1987;138:1397.

  14. Toner GC, Panicek DM, Heelan RT. Adjuntive surgery after chemotherapy for nonseminomatous germ cell tumors. Recomendations for patient selection. J Clin Oncol 1990;8:1638.

  15. Tait D, Peckham MJ, Hendry WF. Postchemotherapy surgery in advanced non-seminomatous germ cell testicular tumors. The significance of histology with particular reference to differentiated (mature) teratoma. Br J Cancer 1984;50:601.

  16. Gelderman WA, Schraffordt, Koops H. Results of adjuvant surgery in patients with stage III and IV nonseminomatous testicular tumors after cisplatin vinblastine-bleomycin chemotherapy. J Surg Oncol 1988;38:227.

  17. Jansen RHL, Sylvester R, Sleyfer DT. Long term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at post-chemotherapy surgery. Eur J Cancer 1991;27:695.

  18. Einhorn LH, Williams SD, Mandelbaum I. Surgical resection in disseminated testicular cancerfollowing chemotherapeutic cytoreduction. Cancer 1981;48:904.

  19. Nichols C, Tricot G, Williams S. Dose-intensive chemotherapy in refractory germ sell cancer- A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Onco 1989;7:932.

  20. Molenaar WM, Oosterhuis JW, Meiring A. Histology and DNA contents of a secundary malignancy arising in a mature residual lesion six year after chemotherapy for a disseminated nonseminomatous testicular tumor. Cancer 1986;58:264.

  21. Fossa SD, Ous S, Lien HH. Post-chemotherapy lymph node histology in radiologically normal patients with metastatic nonseminomatous testicular cancer. J Urol 1989; 141.557.

  22. Roth BH, Greist A, Kubulis PS. Cisplatin-based combination chemotherapy for disseminated germ cell tumors. Long-term follow-up. J Clin Oncol 1988;6:239.

  23. Fossa SD, Wvist H, Stenwig AE. Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses? J Clin Oncol 1992;10:569.

  24. Bosl GJ, Geller NL, Cirrincione C. Multivariate analysis of prognostic variables in patients with metastatic testicular cancer. Cancer Res 1983;43:3403.

  25. Bajorin DF, Herr HW, Motzer RJ. Current perspectives on the role of adjuntive surgery in combined modality treatment of patients with germ cell tumors. Semin Oncol 1992;19: 148.

  26. Donohue JP, Rowland RG, Kopecky K. Correlation of computerized tomographic changes and histological findings in 80 patients havingradical retroperitoneal lymph node dissection after chemotherapy for testis cancer. J Urol 1987;137:1176.

  27. Einhorn LH, Williams SD, Mandelbaum I. Surgical resection in disseminated testicular cancer followingchemotherapeutic cytoreduction. Cancer 1981;48:904.

  28. Medical Research Council Working Party on Testicular tumors. Prognostic factors in advanced non-seminomatous germ-cell testicular tumors. Results of a multicenter study. Lancet 1985;1:8.

  29. Droz JP, Kramar A, Rey A. Prognostic factors inmetastatic disease. Semin Oncol 1992; 2:181.

  30. Loehrer PJ, Elson P, Johnson DH. Arandomized trialof cisplatin plus etoposide with and without bleomycin in favorable prognosis disseminated germ cell tumors. An ECOG study. Proc Am Soc Clin Oncol1991; 10:169, (abstr).

  31. Motzer R, Gulati SC, Crown J. High dose carboplatin+etoposide with autologous bone marrow rescue in poor risk nonseminomatous germ cell tumor patients with slow serum tumor marker decline during induction with cyclophosphamide, bleomycin, actinomycin D, cisplatin (VAB-6). Proc Am Soc Clin Oncol 1991; 10:164, (abstr).

  32. Tiffany P, Morse MJ, Bosl G. Sequential excision of residual thoracic and retroperitoneal masses after chemotherapy for stage III germ cell tumors. Cancer 1986; 57:978.

    QUIMIOTERAPIA DEL CARCINOMA DE TESTíCULO

  1. Hoskin P, Dilly S, Easton D et al. Prognostic factors in stage I non seminomatous germ cell testicular tumors managed by orchiectomy and surveillance: implications for adjuvant chemotherapy. J Clin Oncol 1986;4.1031

  2. Klepp O, Olsson AM, Hernikson H et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study Swedish-Norwegian Testicular Cancer Group. J Clin Oncol 1990;8.509.

  3. Zagars GK, Babian RJ. Stage I testicular seminoma: rationale for post orchiectomy radiation therapy. Int J Radiat Oncol Biol Phys 1987;13.155.

  4. Oliver RTD, Ong J, Ostrwski J et al. Radiotherapy, surveillance or platinum based adjuvant chemotherapy for stage I germ cell tumors. Proc Amer Soc Clin Oncol 1993; 12.231.

  5. Saxman SB, Nichols CR, Foster RJ et al. The management of patients with clinical stage A testicular non seminomatous germ cell tumors (NSGCT) and persistently elevated serologic markers. Proc Amer Soc Clin Oncol 1995;14.230.

  6. International Germ cell Cancer Collaborative Group. International germ cell consensus classification. A prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol 1997;15.594.

  7. Aass N, Lepp O, Cavallin-Stahl E et al. Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience. J Clin Oncol 1991;9.818.

  8. Bosl GJ, Bajorin DF, Sheinferl J, Motzer R. Cancer of the testis. En: DeVita V, Hellman S, Rosenberg SA ed. Cancer principles & practice of oncology. 5th. edition. Philadelphia: Lippincott-Raven, 1997:1397.

  9. Einhorn L, Williams S, Troner M et al. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 1981; 305.727.

  10. Donohue J, Rowland R, Kopecky K et al. Correlation of computerized tomographic changes and histological findings in 80 patientes having radical retroperitoneal lymph node dissection after chemotherapy for testis tumor. J Urol 1987;137.1176.
Contenido
Copyright © 2005 Dr. Scope. Derechos Reservados.
Diseño y Programación: Educación Médica Contínua